अApnaFunda
Menu

KILITCH DRUGS (I) LTD (KILITCH)

Health Technology

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.54 / 100
Profitability 29Growth 81Balance sheet 53
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.55 / 100
Price 78Earnings 33
Divergence: price ahead of business (2 months)
Compare withSUN PHARMACEUTICAL INDUSTRIESDIVIS LABORATORIES LIMITEDTORRENT PHARMACEUTICALS LTD

Passes these screens: Price ahead of business

Share Price
₹201.32
P/E
23.4x
ROCE
13.0%
Market Cap
₹705 cr
Revenue (TTM)
₹237 cr
P/S
3.0x
P/B
2.5x
ROE
10.7%
Operating Margin
6.5%
Debt / Equity
0.3x
Promoter Holding
63.8%
12M Momentum
3.7%
P/E vs its own history13th percentilesince Jan '19
P/E vs Health Technology0.7xthe sector median

52-week range

₹117.25₹267.90
56% of the way from its 52-week low to its high

Price risk

1Y volatility
48.2%
Beta vs sector
1-year daily
1.07

Balance sheet & cash

Interest cover
operating profit ÷ interest
9.0x
Cash from profit, 3Y
operating cash flow ÷ net profit
0.58x
Share count, 1Y
+118.8%

Was the rally earned?

+4%share price, 1 yearRoughly flat
  • The share price was roughly flat over 1 year (+4%).
  • The share count barely moved.
1 year Net profit growth: +9 pts. Points of the price return explained by net profit growing (or shrinking).+9 ptsP/E change: -4 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.-4 ptsShare count change: -2 pts. Points of the price return explained by the share count changing. More shares count against the price.-2 pts +4% 1 year Net profit growth: +9 pts. Points of the price return explained by net profit growing (or shrinking).+9 ptsP/E change: -4 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.-4 ptsShare count change: -2 pts. Points of the price return explained by the share count changing. More shares count against the price. +4%
Net profit growth+9 ptsNet profit rose about 9%, which lifts the price.
P/E change-4 ptsThe P/E fell from 24.3x to 23.4x, which lowers the price.
Share count change-2 ptsShare count was little changed. More shares would count against the price.
+49%share price, 3 yearsLower P/E held it back

Mostly yes, with a catch.

  • Per-share earnings added 126 points, but investors now pay less per rupee of profit (P/E 44.0x to 23.4x), which took 77 points back.
  • The share count rose 31%.
3 years Net profit growth: +159 pts. Points of the price return explained by net profit growing (or shrinking).+159 ptsP/E change: -77 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.-77 ptsShare count change: -33 pts. Points of the price return explained by the share count changing. More shares count against the price.-33 pts +49% 3 years Net profit growth: +159 pts. Points of the price return explained by net profit growing (or shrinking).+159 ptsP/E change: -77 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.-77 ptsShare count change: -33 pts. Points of the price return explained by the share count changing. More shares count against the price. +49%
Net profit growth+159 ptsNet profit rose about 265%, which lifts the price.
P/E change-77 ptsThe P/E fell from 44.0x to 23.4x, which lowers the price.
Share count change-33 ptsShare count rose 31%, which lowers the price.
+167%share price, 5 yearsLower P/E held it back

Mostly yes, with a catch.

  • Per-share earnings added 351 points, but investors now pay less per rupee of profit (P/E 69.3x to 23.4x), which took 184 points back.
  • The share count rose 133%.
5 years Net profit growth: +495 pts. Points of the price return explained by net profit growing (or shrinking).+495 ptsP/E change: -184 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.-184 ptsShare count change: -144 pts. Points of the price return explained by the share count changing. More shares count against the price.-144 pts +167% 5 years Net profit growth: +495 pts. Points of the price return explained by net profit growing (or shrinking).+495 ptsP/E change: -184 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.-184 ptsShare count change: -144 pts. Points of the price return explained by the share count changing. More shares count against the price. +167%
Net profit growth+495 ptsNet profit rose about 1740%, which lifts the price.
P/E change-184 ptsThe P/E fell from 69.3x to 23.4x, which lowers the price.
Share count change-144 ptsShare count rose 133%, which lowers the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

Is it expensive against its own past and its peers?

23.4xP/E todayNear its historic low
Against its own history13th percentileMedian 44.1x; usual range 22.6x to 166.0x since 2019-01.
Against Health Technology23.4x vs 35.4xBelow the Health Technology median.
16.6x117.5x218.3x319.2xJan '19Aug '20Mar '22Oct '23May '25Oct '2616.6x117.5x218.3x319.2xJan '19Aug '21Mar '24Oct '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dashed line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

What is the price implying?

~24%annual earnings growth implied by the price

At a P/E of 41.2x, the price would imply about 23.9%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Fewer than six years of annual earnings are available, which is too little to measure delivered growth.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

What changed?

  1. Oct '26Regained the 2025-07 peak, 7 months after the low.
  2. Oct '26Volume reached 25.7x its 50-day median on 2026-10-06; price +11.5% that day.
  3. Sep '26Slipped to the bottom quartile of Health Technology on operating margin (from the 2nd quartile).
  4. Jun '26Revenue (TTM) reached a new high of ₹235 cr.
  5. Jun '26Slipped to the 3rd quartile of Health Technology on ROCE (from the 2nd quartile).
  6. Jun '26Share count is up 118.8% over 12 months.
  7. May '26Volume reached 40.9x its 50-day median on 2026-05-18; price +10.0% that day.
  8. Mar '26Fell 48% from the Jul 2025 peak to the Mar 2026 low.
Show 22 earlier events
  1. Feb '26Volume reached 12.4x its 50-day median on 2026-02-05; price +6.9% that day.
  2. Dec '25Promoter holding fell 5.5 pts to 63.8%.
  3. Oct '25Volume reached 34.9x its 50-day median on 2025-10-28; price -0.0% that day.
  4. Sep '25Slipped to the 3rd quartile of Health Technology on operating margin (from the 2nd quartile).
  5. Aug '25Volume reached 8.6x its 50-day median on 2025-08-28; price -5.0% that day.
  6. Jun '25P/E fell below the 10th percentile of its own history to date (28.8x).
  7. Jun '25Moved into the 2nd quartile of Health Technology on ROCE (from the 3rd quartile).
  8. May '25Regained the 2024-02 peak, 6 months after the low.
  9. Apr '25Volume reached 44.4x its 50-day median on 2025-04-29; price +12.1% that day.
  10. Mar '25Moved into the top quartile of Health Technology on EPS growth (from the 2nd quartile).
  11. Mar '25Volume reached 7.9x its 50-day median on 2025-03-18; price +4.7% that day.
  12. Dec '24Revenue (TTM) reached a new high of ₹158 cr.
  13. Dec '24P/E fell below the 10th percentile of its own history to date (34.0x).
  14. Dec '24Moved into the 3rd quartile of Health Technology on operating margin (from the bottom quartile).
  15. Nov '24Fell 35% from the Feb 2024 peak to the Nov 2024 low.
  16. Nov '24Volume reached 38.7x its 50-day median on 2024-11-13; price +9.4% that day.
  17. Sep '24Slipped to the bottom quartile of Health Technology on operating margin (from the 2nd quartile).
  18. Jul '24Volume reached 28.3x its 50-day median on 2024-07-22; price +3.0% that day.
  19. Jun '24Revenue (TTM) reached a new high of ₹154 cr.
  20. Jun '24Slipped to the 2nd quartile of Health Technology on EPS growth (from the top quartile).
  21. Jun '24Volume reached 8.5x its 50-day median on 2024-06-26; price +5.3% that day.
  22. Nov '23Volume reached 16.4x its 50-day median on 2023-11-02; price +5.0% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Are profits backed by cash?

1 of 7 checks are within range, 4 near a threshold, 2 beyond a threshold.
Tap a check to see how it is measured.

Other income reliance30%Near threshold

Other income as a share of pre-tax profit (trailing twelve months): 29.6%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate28%Within range

Median quarterly effective tax rate over about 2.5 years: 28.5%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion0.58xNear threshold

Operating cash flow divided by net profit over the last three fiscal years: 0.58x (cash from operations ₹40 cr, net profit ₹69 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow0 of 5 yrsBeyond threshold

Fiscal years with positive free cash flow in the last 5: 0. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+37 daysNear threshold

Debtor days are above the median of the previous three fiscal years by 37 days (186 vs 149). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress209% of fixed assetsBeyond threshold

Capital work-in-progress is 209% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+112 days / 2 yrsNear threshold

Days payable changed by +112 over two years. Bands: rise of up to 30 days; more than 30 days.

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 2 years, promoters trimmed 5.5 pts.
  • The number of shareholders rose from 9,062 to 12,627 (+39%) between Dec 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupDec '23Jun '26Change
Promoters69.2%63.8%-5.5 pts
FIIs0.0%0.1%+0.1 pts
DIIs0.0%0.0%0.0 pts
Public and others30.8%36.1%+5.3 pts

Number of shareholders

12,627shareholders+39% since Dec '23
9k10k11k13k Dec '23Dec '24Sep '25Mar '26Jun '26
Dec '23: 9,062
Mar '24: 9,525
Dec '24: 10,139
Mar '25: 9,749
Sep '25: 10,929
Dec '25: 12,043
Mar '26: 11,785
Jun '26: 12,627
 9k10k11k13k Dec '23Mar '25Mar '26Jun '26
Dec '23: 9,062
Mar '24: 9,525
Dec '24: 10,139
Mar '25: 9,749
Sep '25: 10,929
Dec '25: 12,043
Mar '26: 11,785
Jun '26: 12,627

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

How rough has the ride been?

Maximum drawdown-68.9%recovered 2021-12
1-year volatility48.2%annualised
Beta vs sector index0.763-year daily, correlation 0.26
Volume spikes3last 90 sessions, 5x the 50-day median

Monthly share price

₹39₹100₹160₹221 Jan '19Aug '20Mar '22Oct '23May '25Oct '26
2019-01: ₹104.55
2019-02: ₹90.40
2019-03: ₹95.40
2019-04: ₹91.90
2019-05: ₹84.75
2019-06: ₹71.90
2019-07: ₹53.85
2019-08: ₹51.25
2019-09: ₹59.20
2019-10: ₹57.25
2019-11: ₹56.80
2019-12: ₹62.30
2020-01: ₹59.00
2020-02: ₹49.50
2020-03: ₹40.05
2020-04: ₹51.60
2020-05: ₹44.25
2020-06: ₹48.30
2020-07: ₹42.10
2020-08: ₹44.15
2020-09: ₹40.10
2020-10: ₹43.90
2020-11: ₹45.60
2020-12: ₹47.15
2021-01: ₹43.20
2021-02: ₹42.95
2021-03: ₹39.30
2021-04: ₹51.95
2021-05: ₹79.80
2021-06: ₹76.40
2021-07: ₹107.50
2021-08: ₹84.50
2021-09: ₹81.45
2021-10: ₹75.50
2021-11: ₹76.30
2021-12: ₹122.10
2022-01: ₹109.65
2022-02: ₹82.90
2022-03: ₹81.90
2022-04: ₹91.40
2022-05: ₹83.70
2022-06: ₹76.20
2022-07: ₹79.30
2022-08: ₹83.00
2022-09: ₹80.70
2022-10: ₹86.40
2022-11: ₹76.40
2022-12: ₹76.15
2023-01: ₹73.80
2023-02: ₹69.30
2023-03: ₹68.10
2023-04: ₹85.25
2023-05: ₹95.75
2023-06: ₹94.90
2023-07: ₹91.10
2023-08: ₹90.20
2023-09: ₹121.80
2023-10: ₹135.50
2023-11: ₹161.50
2023-12: ₹180.70
2024-01: ₹213.00
2024-02: ₹188.60
2024-03: ₹190.30
2024-04: ₹177.50
2024-05: ₹165.15
2024-06: ₹163.60
2024-07: ₹183.10
2024-08: ₹162.80
2024-09: ₹168.00
2024-10: ₹156.90
2024-11: ₹154.40
2024-12: ₹159.60
2025-01: ₹153.55
2025-02: ₹151.20
2025-03: ₹177.40
2025-04: ₹197.00
2025-05: ₹215.80
2025-06: ₹216.30
2025-07: ₹220.50
2025-08: ₹169.65
2025-09: ₹169.00
2025-10: ₹194.20
2025-11: ₹171.05
2025-12: ₹175.10
2026-01: ₹157.00
2026-02: ₹161.75
2026-03: ₹124.45
2026-04: ₹154.02
2026-05: ₹182.39
2026-06: ₹194.73
2026-07: ₹186.59
2026-08: ₹174.64
2026-09: ₹213.32
2026-10: ₹201.32
 ₹39₹100₹160₹221 Jan '19Aug '21Mar '24Oct '26
2019-01: ₹104.55
2019-02: ₹90.40
2019-03: ₹95.40
2019-04: ₹91.90
2019-05: ₹84.75
2019-06: ₹71.90
2019-07: ₹53.85
2019-08: ₹51.25
2019-09: ₹59.20
2019-10: ₹57.25
2019-11: ₹56.80
2019-12: ₹62.30
2020-01: ₹59.00
2020-02: ₹49.50
2020-03: ₹40.05
2020-04: ₹51.60
2020-05: ₹44.25
2020-06: ₹48.30
2020-07: ₹42.10
2020-08: ₹44.15
2020-09: ₹40.10
2020-10: ₹43.90
2020-11: ₹45.60
2020-12: ₹47.15
2021-01: ₹43.20
2021-02: ₹42.95
2021-03: ₹39.30
2021-04: ₹51.95
2021-05: ₹79.80
2021-06: ₹76.40
2021-07: ₹107.50
2021-08: ₹84.50
2021-09: ₹81.45
2021-10: ₹75.50
2021-11: ₹76.30
2021-12: ₹122.10
2022-01: ₹109.65
2022-02: ₹82.90
2022-03: ₹81.90
2022-04: ₹91.40
2022-05: ₹83.70
2022-06: ₹76.20
2022-07: ₹79.30
2022-08: ₹83.00
2022-09: ₹80.70
2022-10: ₹86.40
2022-11: ₹76.40
2022-12: ₹76.15
2023-01: ₹73.80
2023-02: ₹69.30
2023-03: ₹68.10
2023-04: ₹85.25
2023-05: ₹95.75
2023-06: ₹94.90
2023-07: ₹91.10
2023-08: ₹90.20
2023-09: ₹121.80
2023-10: ₹135.50
2023-11: ₹161.50
2023-12: ₹180.70
2024-01: ₹213.00
2024-02: ₹188.60
2024-03: ₹190.30
2024-04: ₹177.50
2024-05: ₹165.15
2024-06: ₹163.60
2024-07: ₹183.10
2024-08: ₹162.80
2024-09: ₹168.00
2024-10: ₹156.90
2024-11: ₹154.40
2024-12: ₹159.60
2025-01: ₹153.55
2025-02: ₹151.20
2025-03: ₹177.40
2025-04: ₹197.00
2025-05: ₹215.80
2025-06: ₹216.30
2025-07: ₹220.50
2025-08: ₹169.65
2025-09: ₹169.00
2025-10: ₹194.20
2025-11: ₹171.05
2025-12: ₹175.10
2026-01: ₹157.00
2026-02: ₹161.75
2026-03: ₹124.45
2026-04: ₹154.02
2026-05: ₹182.39
2026-06: ₹194.73
2026-07: ₹186.59
2026-08: ₹174.64
2026-09: ₹213.32
2026-10: ₹201.32

Last 90 trading days

₹158₹192₹227₹261 Jun 23Jul 20Aug 13Sep 8Oct 6Oct 30
2026-06-23: ₹191.99
2026-06-25: ₹185.31
2026-06-30: ₹194.73
2026-07-02: ₹196.99
2026-07-06: ₹192.51
2026-07-08: ₹183.12
2026-07-10: ₹183.10
2026-07-14: ₹175.34
2026-07-16: ₹182.75
2026-07-20: ₹178.15
2026-07-22: ₹178.18
2026-07-24: ₹180.01
2026-07-28: ₹183.59
2026-07-30: ₹190.58
2026-08-03: ₹190.86
2026-08-05: ₹191.38
2026-08-07: ₹193.52
2026-08-11: ₹191.46
2026-08-13: ₹191.22
2026-08-17: ₹172.58
2026-08-19: ₹158.10
2026-08-21: ₹162.33
2026-08-25: ₹171.04
2026-08-27: ₹171.33
2026-08-31: ₹174.64
2026-09-02: ₹171.37
2026-09-04: ₹180.95
2026-09-08: ₹187.88
2026-09-10: ₹185.03
2026-09-15: ₹190.20
2026-09-17: ₹188.67
2026-09-21: ₹201.02
2026-09-23: ₹221.62
2026-09-25: ₹224.27
2026-09-29: ₹216.76
2026-10-01: ₹218.51
2026-10-06: ₹260.70
2026-10-08: ₹244.30
2026-10-12: ₹239.14
2026-10-14: ₹230.37
2026-10-16: ₹230.40
2026-10-21: ₹203.78
2026-10-23: ₹202.24
2026-10-27: ₹207.53
2026-10-29: ₹209.14
2026-10-30: ₹201.32
 ₹158₹192₹227₹261 Jun 23Aug 5Sep 17Oct 30
2026-06-23: ₹191.99
2026-06-25: ₹185.31
2026-06-30: ₹194.73
2026-07-02: ₹196.99
2026-07-06: ₹192.51
2026-07-08: ₹183.12
2026-07-10: ₹183.10
2026-07-14: ₹175.34
2026-07-16: ₹182.75
2026-07-20: ₹178.15
2026-07-22: ₹178.18
2026-07-24: ₹180.01
2026-07-28: ₹183.59
2026-07-30: ₹190.58
2026-08-03: ₹190.86
2026-08-05: ₹191.38
2026-08-07: ₹193.52
2026-08-11: ₹191.46
2026-08-13: ₹191.22
2026-08-17: ₹172.58
2026-08-19: ₹158.10
2026-08-21: ₹162.33
2026-08-25: ₹171.04
2026-08-27: ₹171.33
2026-08-31: ₹174.64
2026-09-02: ₹171.37
2026-09-04: ₹180.95
2026-09-08: ₹187.88
2026-09-10: ₹185.03
2026-09-15: ₹190.20
2026-09-17: ₹188.67
2026-09-21: ₹201.02
2026-09-23: ₹221.62
2026-09-25: ₹224.27
2026-09-29: ₹216.76
2026-10-01: ₹218.51
2026-10-06: ₹260.70
2026-10-08: ₹244.30
2026-10-12: ₹239.14
2026-10-14: ₹230.37
2026-10-16: ₹230.40
2026-10-21: ₹203.78
2026-10-23: ₹202.24
2026-10-27: ₹207.53
2026-10-29: ₹209.14
2026-10-30: ₹201.32

Drawdown from peak

0% -33% -65% Jan '19Dec '22Oct '26 0% -33% -65% Jan '19Dec '22Oct '26
Largest drawdowns

-68.9% (2019-01 peak to 2020-03 low, recovered 2021-12)

-51.6% (2022-01 peak to 2023-03 low, recovered 2023-10)

-48.5% (2025-07 peak to 2026-03 low, recovered 2026-10)

Most recent volume spikes

2026-10-07: 6.8x the 50-day median, price -1.7% that day

2026-10-06: 25.7x the 50-day median, price +11.5% that day

2026-10-05: 10.1x the 50-day median, price +7.0% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Nov '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Oct '26
Lower rank Higher rank

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

CompanySectorSimilarityClosest on
DMCC SPECIALITY CHEMICALS (DMCC)Process Industries62%market cap, revenue growth
MMP INDUSTRIES (MMP)Non-Energy Minerals62%ROCE, P/E
PATEL RETAIL (PATELRMART)Retail Trade59%operating margin, market cap
KANPUR PLASTIPACK (KANPRPLA)Producer Manufacturing58%market cap, operating margin
SHREE PUSHKAR CHEMICALS (SHREEPUSHK)Process Industries58%ROCE, P/E
WINDLAS BIOTECH (WINDLAS)Health Technology47%promoter holding, revenue growth
MIC ELECTRONICS (MICEL)Health Technology45%revenue, operating margin
NGL FINE CHEM (NGLFINE)Health Technology45%EPS growth, debt/equity

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What happened next to similar setups

0%typical 12-month return vs the marketNot meaningfully different from the base rate
  • We found 50 past situations where a non-financial company looked like KILITCH DRUGS (I) LTD today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −23% to +22% vs the market, against +2% for all non-financial companies in the same months.
  • The gap against the base rate (−2.0%, 80% range −16.4% to +2.3%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

−100%−50%0%+50%+100%
GOYALSALT · Oct 2025: −48.5% vs market
EXXARO · Apr 2023: −41.8% vs market
KOLTEPATIL · Apr 2024: −38.0% vs market
HUHTAMAKI · Aug 2020: −35.5% vs market
GANESHBE · May 2023: −35.3% vs market
SHREEPUSHK · May 2022: −34.4% vs market
INTLCONV · Aug 2023: −33.6% vs market
AARTIDRUGS · Aug 2023: −30.9% vs market
SANDHAR · Jan 2020: −30.6% vs market
JKIL · Mar 2021: −30.2% vs market
REPL · Nov 2023: −29.5% vs market
CARYSIL · Jan 2024: −25.9% vs market
TCI · Mar 2020: −24.2% vs market
HARSHA · Feb 2025: −20.8% vs market
SIGACHI · Nov 2023: −20.6% vs market
SHALBY · Sep 2023: −18.8% vs market
JINDRILL · Apr 2024: −18.1% vs market
5PAISA · Sep 2023: −15.9% vs market
LIBERTSHOE · Jun 2020: −15.4% vs market
SUBROS · Mar 2021: −14.1% vs market
DICIND · Jun 2020: −13.2% vs market
MBAPL · Feb 2020: −12.5% vs market
BBL · Apr 2024: −11.4% vs market
SINTERCOM · May 2020: −11.0% vs market
PLASTIBLEN · Jan 2020: −0.3% vs market
ADOR · Apr 2020: +0.3% vs market
AIRAN · Sep 2023: +2.2% vs market
MOLDTKPAC · Jan 2020: +4.0% vs market
GNA · Feb 2021: +4.5% vs market
NIPPOBATRY · May 2020: +5.0% vs market
KRSNAA · Dec 2023: +6.6% vs market
VIMTALABS · May 2022: +8.6% vs market
SUPRAJIT · Apr 2021: +10.2% vs market
VADILALIND · Mar 2020: +11.0% vs market
BHAGCHEM · Jun 2023: +11.4% vs market
MINDACORP · Jun 2022: +16.7% vs market
PIXTRANS · Mar 2024: +18.0% vs market
APCOTEXIND · Feb 2022: +23.3% vs market
TTKHLTCARE · Oct 2022: +28.5% vs market
GENUSPOWER · Dec 2020: +29.8% vs market
CENTURYPLY · Jan 2020: +30.0% vs market
GANECOS · Jul 2022: +41.5% vs market
NRBBEARING · Apr 2023: +41.8% vs market
JASH · May 2023: +43.8% vs market
ARTEMISMED · Mar 2023: +68.4% vs market
THEMISMED · Sep 2020: +71.6% vs market
HIKAL · Jan 2021: +81.8% vs market
DOLLAR · Jan 2021: +105.0% vs market
TDPOWERSYS · Nov 2022: +119.6% vs market
SMSPHARMA · May 2020: +137.0% vs market
Similar setups 0%All companies +2.0%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 3 beyond the range shown, drawn at the edge

Similar setups' median
0%
All companies' median
+2.0%
Beat the market
50% vs 52%

50 past situations · 50 companies · 32 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
PLASTIBLEN
Process Industries		 Jan 2020 17x14% +13%−12% 0%
ADOR
Producer Manufacturing		 Apr 2020 13x14% −27%−35% 0%
GANESHBE
Transportation		 May 2023 29x16% +26%−13% −35%
NRBBEARING
Producer Manufacturing		 Apr 2023 20x15% +23%−17% +42%
SHALBY
Health Services		 Sep 2023 38x10% +83%−8% −19%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
GANECOS
Process Industries		 Jul 2022 22x12% +22%−19% +42%
TDPOWERSYS
Producer Manufacturing		 Nov 2022 24x16% +39%−19% +120%
NIPPOBATRY
Producer Manufacturing		 May 2020 9x15% −11%−28% +5%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: P/E, drawdown from 12-month high and 12-month momentum. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to KILITCH DRUGS (I) LTD. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-10-30. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 97,430 company-months from 2000 companies; financial: 5,632 company-months from 106 companies. 2240 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.
Monthly history (94 months)
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1023.4x₹237 cr10.7%13.0%0.3x
2026-0924.8x₹237 cr10.7%13.0%0.3x
2026-0820.2x₹235 cr10.9%13.0%0.3x
2026-0721.6x₹235 cr10.9%13.0%0.3x
2026-0622.6x₹235 cr10.9%13.0%0.3x
2026-0524.5x₹207 cr12.7%16.0%0.2x
2026-0420.7x₹207 cr12.7%16.0%0.2x
2026-0316.7x₹207 cr12.7%16.0%0.2x
2026-0220.5x₹209 cr13.3%16.0%0.2x
2026-0119.9x₹209 cr13.3%16.0%0.2x
2025-1222.2x₹209 cr13.3%16.0%0.2x
2025-1121.4x₹208 cr13.6%16.0%0.2x
2025-1024.3x₹208 cr13.6%16.0%0.2x
2025-0921.1x₹208 cr13.6%16.0%0.2x
2025-0822.6x₹198 cr12.5%16.0%0.2x
2025-0729.4x₹198 cr12.5%16.0%0.2x
2025-0628.8x₹198 cr12.5%16.0%0.2x
2025-0538.7x₹182 cr10.5%13.0%0.2x
2025-0435.4x₹182 cr10.5%13.0%0.2x
2025-0331.8x₹182 cr10.5%13.0%0.2x
2025-0232.2x₹158 cr8.3%13.0%0.2x
2025-0132.7x₹158 cr8.3%13.0%0.2x
2024-1234.0x₹158 cr8.3%13.0%0.2x
2024-1143.0x₹151 cr6.2%13.0%0.2x
2024-1043.7x₹151 cr6.2%13.0%0.2x
2024-0946.8x₹151 cr6.2%13.0%0.2x
2024-0838.8x₹154 cr7.9%13.0%0.2x
2024-0743.6x₹154 cr7.9%13.0%0.2x
2024-0639.0x₹154 cr7.9%13.0%0.2x
2024-0553.6x₹140 cr5.4%10.0%0.1x
2024-0457.6x₹140 cr5.4%10.0%0.1x
2024-0361.8x₹140 cr5.4%10.0%0.1x
2024-0261.2x₹140 cr5.4%10.0%0.1x
2024-0169.2x₹140 cr5.4%10.0%0.1x
2023-1258.7x₹140 cr5.4%10.0%0.1x
2023-1152.4x₹140 cr5.4%10.0%0.1x
2023-1044.0x₹140 cr5.4%10.0%0.1x
2023-0939.5x₹140 cr5.4%10.0%0.1x
2023-0829.3x₹140 cr5.4%10.0%0.1x
2023-0729.6x₹140 cr5.4%10.0%0.1x
2023-0630.8x₹140 cr5.4%10.0%0.1x
2023-0544.1x₹114 cr4.4%6.0%0.1x
2023-0439.3x₹114 cr4.4%6.0%0.1x
2023-0331.4x₹114 cr4.4%6.0%0.1x
2023-0231.9x₹114 cr4.4%6.0%0.1x
2023-0134.0x₹114 cr4.4%6.0%0.1x
2022-1235.1x₹114 cr4.4%6.0%0.1x
2022-1135.2x₹114 cr4.4%6.0%0.1x
2022-1039.8x₹114 cr4.4%6.0%0.1x
2022-0937.2x₹114 cr4.4%6.0%0.1x
2022-0838.2x₹114 cr4.4%6.0%0.1x
2022-0736.5x₹114 cr4.4%6.0%0.1x
2022-0635.1x₹114 cr4.4%6.0%0.1x
2022-0576.8x₹68 cr1.3%3.0%0.1x
2022-0483.9x₹68 cr1.3%3.0%0.1x
2022-0375.1x₹68 cr1.3%3.0%0.1x
2022-0276.1x₹68 cr1.3%3.0%0.1x
2022-01100.6x₹68 cr1.3%3.0%0.1x
2021-12112.0x₹68 cr1.3%3.0%0.1x
2021-1170.0x₹68 cr1.3%3.0%0.1x
2021-1069.3x₹68 cr1.3%3.0%0.1x
2021-0974.7x₹68 cr1.3%3.0%0.1x
2021-0877.5x₹68 cr1.3%3.0%0.1x
2021-0798.6x₹68 cr1.3%3.0%0.1x
2021-0670.1x₹68 cr1.3%3.0%0.1x
2021-05319.2x₹53 cr0.3%1.0%0.1x
2021-04207.8x₹53 cr0.3%1.0%0.1x
2021-03157.2x₹53 cr0.3%1.0%0.1x
2021-02171.8x₹53 cr0.3%1.0%0.1x
2021-01172.8x₹53 cr0.3%1.0%0.1x
2020-12188.6x₹53 cr0.3%1.0%0.1x
2020-11182.4x₹53 cr0.3%1.0%0.1x
2020-10175.6x₹53 cr0.3%1.0%0.1x
2020-09160.4x₹53 cr0.3%1.0%0.1x
2020-08176.6x₹53 cr0.3%1.0%0.1x
2020-07168.4x₹53 cr0.3%1.0%0.1x
2020-06193.2x₹53 cr0.3%1.0%0.1x
2020-0538.5x₹82 cr1.4%6.0%0.1x
2020-0444.9x₹82 cr1.4%6.0%0.1x
2020-0334.8x₹82 cr1.4%6.0%0.1x
2020-0243.0x₹82 cr1.4%6.0%0.1x
2020-0151.3x₹82 cr1.4%6.0%0.1x
2019-1254.2x₹82 cr1.4%6.0%0.1x
2019-1149.4x₹82 cr1.4%6.0%0.1x
2019-1049.8x₹82 cr1.4%6.0%0.1x
2019-0951.5x₹82 cr1.4%6.0%0.1x
2019-0844.6x₹82 cr1.4%6.0%0.1x
2019-0746.8x₹82 cr1.4%6.0%0.1x
2019-0662.5x₹82 cr1.4%6.0%0.1x
2019-0549.3x₹51 cr4.6%5.0%0.0x
2019-0453.4x₹51 cr4.6%5.0%0.0x
2019-0355.5x₹51 cr4.6%5.0%0.0x
2019-0252.6x₹51 cr4.6%5.0%0.0x
2019-0160.8x₹51 cr4.6%5.0%0.0x

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback